Bio


Patricia Garcia, MD is a board certified gastroenterologist and fellowship trained neurogastroenterologist who specializes in treating disorders of gastrointestinal motility including trouble swallowing, heartburn, reflux, constipation, fecal incontinence and pelvic floor dysfunction.

Clinical Focus


  • Gastroenterology
  • Neurogastroenterology and Motility

Academic Appointments


Administrative Appointments


  • Associate Clinical Information Officer, Ambulatory Care, Stanford Health Care (2022 - Present)
  • Director, GI Motility Laboratory, Stanford Digestive Health Center (2018 - Present)

Boards, Advisory Committees, Professional Organizations


  • Member, American Neurogastroenterolgy and Motility Society (2014 - Present)
  • Member, American Gastroenterology Association (2011 - Present)
  • Member, American College of Gastroenterology (2011 - Present)

Professional Education


  • Fellowship, Johns Hopkins University, Neurogastroenterology and Motility (2015)
  • Board Certification: American Board of Internal Medicine, Gastroenterology (2014)
  • Fellowship: New York Presbyterian Hospital of Columbia and Cornell Universities (2014) NY
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2011)
  • Residency: University of Pennsylvania Health System (2011) PA
  • Medical Education: University of Michigan Medical School (2008) MI

All Publications


  • The Impact of Intermittent Fasting on Patients With Suspected Gastroesophageal Reflux Disease. Journal of clinical gastroenterology Jiang, Y., Sonu, I., Garcia, P., Fernandez-Becker, N. Q., Kamal, A. N., Zikos, T. A., Singh, S., Neshatian, L., Triadafilopoulos, G., Goodman, S. N., Clarke, J. O. 2022

    Abstract

    GOAL: The aim was to investigate the short-term impact of time restricted feeding on patients with suspected gastroesophageal reflux disease (GERD).BACKGROUND: Lifestyle modifications are often suggested, but the role of diet in GERD is unclear. Intermittent fasting is popular in the media and has demonstrated potential benefits with weight loss and inflammatory conditions as well as alterations in gastrointestinal hormones.STUDY: Patients who were referred for 96-hour ambulatory wireless pH monitoring off proton pump inhibitor to investigate GERD symptoms were screened for eligibility. Patients were instructed to maintain their baseline diet for the first 2 days of pH monitoring and switch to an intermittent fasting regimen (16 consecutive hour fast and 8h eating window) for the second 2 days. Objective measures of reflux and GERD symptom severity were collected and analyzed.RESULTS: A total of 25 participants were analyzed. 9/25 (36%) fully adhered to the intermittent fasting regimen, with 21/25 (84%) demonstrating at least partial compliance. Mean acid exposure time on fasting days was 3.5% versus 4.3% on nonfasting days. Intermittent fasting was associated with a 0.64 reduction in acid exposure time (95% CI: -2.32, 1.05). There was a reduction in GERD symptom scores of heartburn and regurgitation during periods of intermittent fasting (14.3 vs. 9.9; difference of -4.46, 95% CI: -7.6,-1.32).CONCLUSIONS: Initial adherence to time restricted eating may be difficult for patients. There is weak statistical evidence to suggest that intermittent fasting mildly reduces acid exposure. Our data show that short-term intermittent fasting improves symptoms of both regurgitation and heartburn.

    View details for DOI 10.1097/MCG.0000000000001788

    View details for PubMedID 36730832

  • High Resolution Anorectal Manometry Findings in Men and Women With Parkinson's Disease, Using London Classification Zhou, W., Sinn, D., Jaradeh, S., Muppidi, S., Miglis, M., Triadafilopoulos, G., Halawi, H., Becker, L., Garcia, P., Nguyen, L., Neshatian, L. LIPPINCOTT WILLIAMS & WILKINS. 2022: S407-S408
  • The Effects of Intermittent Fasting on Gastroesophageal Reflux Disease Jiang, Y., Goodman, S., Sonu, I., Garcia, P., Fernandez-Becker, N., Kamal, A., Zikos, T., Singh, S., Neshatian, L., Triadafilopoulos, G., Clarke, J. LIPPINCOTT WILLIAMS & WILKINS. 2021: S214
  • Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea. Digestive diseases and sciences Zikos, T. A., Nguyen, L., Kamal, A., Fernandez-Becker, N., Regalia, K., Nandwani, M., Sonu, I., Garcia, M., Okafor, P., Neshatian, L., Grewal, D., Garcia, P., Triadafilopoulos, G., Clarke, J. O. 2020

    Abstract

    BACKGROUND: Many anti-nausea treatments are available for chronic gastrointestinal syndromes, but data on efficacy and comparative effectiveness are sparse.AIMS: To conduct a sectional survey study of patients with chronic nausea to assess comparative effectiveness of commonly used anti-nausea treatments.METHODS: Outpatients at a single center presenting for gastroenterology evaluation were asked to rate anti-nausea efficacy on a scale of 0 (no efficacy) to 5 (very effective) of 29 commonly used anti-nausea treatments and provide other information about their symptoms. Additional information was collected from the patients' chart. The primary outcome was to determine which treatments were better or worse than average using a t test. The secondary outcome was to assess differential response by individual patient characteristics using multiple linear regression.RESULTS: One hundred and fifty-three patients completed the survey. The mean efficacy score of all anti-nausea treatments evaluated was 1.73. After adjustment, three treatments had scores statically higher than the mean, including marijuana (2.75, p<0.0001), ondansetron (2.64, p<0.0001), and promethazine (2.46, p<0.0001). Several treatments, including many neuromodulators, complementary and alternative treatments, erythromycin, and diphenhydramine had scores statistically below average. Patients with more severe nausea responded better to marijuana (p=0.036) and diphenhydramine (p<0.001) and less so to metoclopramide (p=0.020). There was otherwise no significant differential response by age, gender, nausea localization, underlying gastrointestinal cause of nausea, and GCSI.CONCLUSIONS: When treating nausea in patients with chronic gastrointestinal syndromes, clinicians may consider trying higher performing treatments first, and forgoing lower performing treatments. Further prospective research is needed, particularly with respect to highly effective treatments.

    View details for DOI 10.1007/s10620-020-06195-5

    View details for PubMedID 32185665

  • Recurrent Small Bowel Obstruction with Intraluminal Structures. The journal of trauma and acute care surgery Sun, B. J., Kopecky, K. E., Garcia, P. n., Spain, D. A. 2020

    View details for DOI 10.1097/TA.0000000000002956

    View details for PubMedID 33003015

  • Gastric per-oral endoscopic myotomy: Current status and future directions WORLD JOURNAL OF GASTROENTEROLOGY Podboy, A., Hwang, J., Nguyen, L. A., Garcia, P., Zikos, T. A., Kamal, A., Triadafilopoulos, G., Clarke, J. O. 2019; 25 (21): 2581–90
  • Gastric per-oral endoscopic myotomy: Current status and future directions. World journal of gastroenterology Podboy, A., Hwang, J. H., Nguyen, L. A., Garcia, P., Zikos, T. A., Kamal, A., Triadafilopoulos, G., Clarke, J. O. 2019; 25 (21): 2581-2590

    Abstract

    Gastroparesis, or symptomatic delayed gastric emptying in the absence of mechanical obstruction, is a challenging and increasingly identified syndrome. Medical options are limited and the only medication approved by the Food and Drug Administration for treatment of gastroparesis is metoclopramide, although other agents are frequently used off label. With this caveat, first-line treatments for gastroparesis include dietary modifications, antiemetics and promotility agents, although these therapies are limited by suboptimal efficacy and significant medication side effects. Treatment of patients that fail first-line treatments represents a significant therapeutic challenge. Recent advances in endoscopic techniques have led to the development of a promising novel endoscopic therapy for gastroparesis via endoscopic pyloromyotomy, also referred to as gastric per-oral endoscopic myotomy or per-oral endoscopic pyloromyotomy. The aim of this article is to review the technical aspects of the per-oral endoscopic myotomy procedure for the treatment of gastroparesis, provide an overview of the currently published literature, and outline potential next directions for the field.

    View details for DOI 10.3748/wjg.v25.i21.2581

    View details for PubMedID 31210711

    View details for PubMedCentralID PMC6558440

  • Under Pressure: Do Volume-Based Measurements Define Rectal Hyposensitivity in Clinical Practice? DIGESTIVE DISEASES AND SCIENCES Kamal, A. N., Garcia, P., Clarke, J. O. 2019; 64 (5): 1062–63
  • Under Pressure: Do Volume-Based Measurements Define Rectal Hyposensitivity in Clinical Practice? Digestive diseases and sciences Kamal, A. N., Garcia, P., Clarke, J. O. 2019

    View details for PubMedID 30963367

  • REFRACTORY GASTROPARESIS: GASTRIC PERORAL ENDOSCOPIC MYOTOMY (G-POEM) VS. INTRAPYLORIC BOTULINUM TOXIN INJECTION Parsa, N., Yang, J., Gutierrez, O., Moran, R., Sanaei, O., Fayad, L., Dbouk, M., Paiji, C., Kumbhari, V., Mullin, G., Stein, E. M., Abdi, T., Garcia, P., Kalloo, A. N., Canto, M. I., Clarke, J. O., Khashab, M. A. MOSBY-ELSEVIER. 2018: AB241–AB242